drugset / Trial / NCT07044921
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Phase II clinical study of irinotecan liposome (II)-based combination regimen as a treatment for irinotecan-resistant colorectal cancer.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2026-07-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan Liposomes (II) | Unknown | 47.1 mg/m2 | Intravenous |
| Subject | Irinotecan Liposomes (II) | Unknown | 60 mg/m2 | Intravenous |
| Background | Bevacizumabl | Unknown | 5 mg/kg | Intravenous |
| Background | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |